ICICI Direct starts Stylam Industries at Buy as new plant expands laminate capacity
ICICI Direct has set a ₹4,000 target for Stylam Industries, implying 21% upside from ₹3,314. The brokerage cites the Manak Tabra facility, pricing actions and export growth; the ₹334 crore expansion is expected to add meaningful capacity and support revenue growth through FY27-FY28.
The development
ICICI Direct initiated BUY coverage on Indian decorative-laminates maker Stylam Industries, citing its new Manak Tabra plant, pricing actions and export growth. The brokerage sees a ₹4,000 target, while capacity ramp-up is expected to bolster premium surface demand in India and overseas markets.
The numbers
- BUY target price: ₹4,000
- Implied upside: 21% from ₹3,314
- Manak Tabra facility capacity: 52.5 MSM
- Expansion investment: ₹334 crore
- FY27 facility revenue target: ~₹300 crore
Why it matters to operators and investors
Stylam’s Manak Tabra ramp could increase laminate availability over the next two to three years, strengthening its ability to serve retailer demand and export orders.
What to watch next
- Plant commissioning milestones, commercial production date and monthly utilization trajectory at Manak Tabra.
- Quarterly volume growth versus realization growth, indicating whether revenue is price-led or capacity-led.
- Export order book, geographic mix and any evidence of price competition in key overseas markets.
- EBITDA margin and gross-margin trend after depreciation, startup costs and freight expenses.
- Inventory days, receivable days and operating cash-flow conversion during the ramp.
The counter-case
The ₹700-1,000 crore revenue potential is an aspirational capacity-utilisation outcome, not guaranteed demand. A two-to-three-year ramp could be slower if domestic housing, renovation spending or export orders weaken. New laminate capacity may also pressure industry pricing, while higher wood, paper, resin, freight or energy costs could erode margins if price increases do not stick. The ₹334 crore capex raises execution, commissioning and return-on-capital risk; a 21% target-price upside leaves limited room for delays or earnings misses.